Context Therapeutics has dosed the first subject in the Phase I trial of CTIM-76, targeting gynaecologic and testicular cancers.

Their conclusion that the Biden administration overestimated the risk of escalation underestimates just how hard it is to ...

Around the world, feminist activists have successfully combated autocracy — most recently in South Korea. U.S. grant makers ...

Verismo Therapeutics has commenced the first patient dosing in its multicentre Phase I CELESTIAL-301 trial of SynKIR-310.

The same research team that documented the impact of auto-enrollment and auto-escalation in 401(k) plans has returned to the ...

SAN CARLOS, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next-generation, potentially curative cell ...

Under the deal, Candid will have exclusive global rights to a tri-specific TCE discovered by WuXi using its WuXiBody platform. The Chinese company is set to receive an undisclosed upfront payment, as ...

A visual review of the border situation with China reveals an immediate troop pullback but highlights rapid infrastructure upgrades in disputed areas, casting doubts on China's commitment to long-term ...

As Western powers continue to provide and approve Ukraine’s use of advanced weaponry against Russia, the veracity of Vladimir Putin’s deterrent threats against such provocations is ...